FDA approves 1st head and neck cancer drug in 10 years

The FDA has granted accelerated approval to Rybrevant Faspro for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed on or after platinum-based chemotherapy and immunotherapy. The approval is the first in 10 years for patients with recurrent or metastatic head and neck squamous cell carcinoma who had received prior […] The post FDA approves 1st head and neck cancer drug in 10 years appeared first on Becker's Hospital Review | Healthcare N...